Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326996 · ClinicalTrials.gov registry record · Early Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
A Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06326996: Recruiting Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting, sponsored by University of California, Los Angeles.
NCT06326996 is a Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 52 participants, below the 1,485-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06326996, a Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.
Primary Outcome
Assess thiamine treatment effect on blood lactate levels in CABG patients with and without intervention measured via blood gas analyzer (ABL90 flex plus, Radiometer).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Thiamine
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2026-09-30 |
| Phase | Early Phase 1 |
What NCT06326996 shows while recruiting
NCT06326996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,485-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Coronary Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06326996 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06326996 about?
NCT06326996 is a clinical study titled "Thiamine Intervention and Coronary Artery Bypass Grafting". The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitiv...
What is the current status of trial NCT06326996?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2024-10-10. Estimated completion is 2026-09-30.
What conditions does trial NCT06326996 study?
This clinical trial studies the following conditions: Coronary Heart Disease, Coronary Artery Bypass Grafting.
What interventions are being tested in trial NCT06326996?
The interventions under investigation include: Placebo (DRUG), Thiamine (DRUG).
Who is sponsoring clinical trial NCT06326996?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06326996 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06326996's enrollment target sits among peer trials
52 15th of 19 higher than 5 of 19 other Coronary Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Project 3: ACHIEVE- CHD
RECRUITING · NA
-
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
RECRUITING · NA
-
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
COMPLETED · Phase 2
-
Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids
COMPLETED · NA
-
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
COMPLETED · Phase 3
-
An IT Approach to Implementing Depression Treatment in Cardiac Patients (iHeart DepCare)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI